Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > REGULATORY
REGULATORY
- Chuikyo OKs NHI Price Listing of Anti-HIV Drug Genvoya
June 23, 2016
- Exemption from Bioequivalence Studies Adopted as New Topic at ICH Meeting in Lisbon; Could Affect Generics as Well
June 22, 2016
- Selexipag Designated as Orphan Drug for CTEPH: MHLW
June 21, 2016
- PMDA to Boost Transparency in Expert Consultation Process by Confirming Donations from Competitors
June 21, 2016
- PMDA Beats FY2015 Review Time Targets
June 20, 2016
- MHLW Unveils List of Switch OTCs Eligible for Tax Break
June 20, 2016
- Anti-HIV Drug Genvoya Approved in Japan
June 20, 2016
- MHLW Reprimands Bipha Over Leakage of Recombinant Organisms in Manufacturing Process for Medway Injection
June 20, 2016
- Kaketsuken-Like Cases Seen Outside Japan Too, Many Exposed through Tip-Offs: PMDA
June 17, 2016
- MHLW Study Group Approves Interim Report toward Full-Scale Operation of MID-NET Database
June 17, 2016
- First Generics for 8 APIs to Join NHI Price List on June 17, 40% Price Rule Applied to Olanzapine
June 16, 2016
- Greater than Expected Need for Drug Discovery Research Using Existing Drugs: AMED Project
June 16, 2016
- MHLW Personnel Reshuffle Announced; Nakayama to Lead FY2018 Drug Pricing Reform
June 15, 2016
- Harvoni, Sovaldi under Review for Risks of Hypertension, Cerebrovascular Disorder
June 13, 2016
- MHLW to Set Up Subcommittee to Help Implement AMR Action Plan
June 13, 2016
- AMED to Establish New Scheme to Support Commercialization of Drug Seeds from Academia
June 10, 2016
- MHLW to Revise Guidelines on Use of Blood Products
June 10, 2016
- Upcoming ICH Meeting Expected to Approve New Members Including Generic Drug Organization
June 9, 2016
- Company Funding for AMED-Backed Clinical Research Also Subject to Legal Regulation: Govt
June 8, 2016
- Use of MID-NET in PMS Could Promote Comparisons of One’s Own Products with Other Treatments: FPMAJ Official
June 7, 2016
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…